Who is Emmanuelle Charpentier
Emmanuelle Charpentier is a French microbiologist, geneticist and biochemist, born on 11 December 1968 in Juvisy-sur-Orge. She shared the 2020 Chemistry Nobel with Jennifer Doudna for developing a genome-editing method. Her research began with mechanisms regulating bacterial life.[2]
Education in France and the United States
She studied biochemistry, microbiology and genetics at Pierre and Marie Curie University in Paris between 1986 and 1992, then conducted doctoral research at the Pasteur Institute from 1992 to 1995. This training combined molecular analysis, genetics and microbiology, foundations for her later research programme.[1]
In 1996 she moved to the United States to work with Elaine Tuomanen at Rockefeller University. She also worked with Pamela Cowin and Richard Novick in New York and at St. Jude in Memphis. Her autobiography describes how studying pathogens and skin genetics revealed a need for more precise genetic tools.[5]
Vienna, Umeå and bacterial research
Between 2002 and 2009 she developed her own group at the University of Vienna, receiving her microbiology habilitation in 2006. Working within the Max Perutz Labs environment, she established an independent programme on bacterial gene regulation and responses to the environment.[6]
In 2004 she published a vector system for Gram-positive bacteria with Anton, Barry, Alfonso, Fang and Novick. Such tools support studies of genetic function in different microorganisms. The paper shows that her interest in experimental instruments preceded CRISPR and was closely connected to bacterial biology.[7]
In 2009 she joined Umeå’s MIMS laboratory in Sweden, later remaining a visiting professor. In 2013 she became a department head at the Helmholtz Centre for Infection Research and a professor in Hannover. Her Alexander von Humboldt professorship began in 2014.[8]
The Regulation in Infection Biology department studied molecular processes in infection and immunity, focusing on Gram-positive pathogens. Examining gene expression, RNA processing and the proteins involved connects cellular mechanisms with bacterial behaviour.[9]
tracrRNA and CRISPR-Cas9 development
In 2011, Deltcheva and colleagues, with Charpentier as senior author, identified tracrRNA’s function in Streptococcus pyogenes. This small RNA helps mature CRISPR guides together with RNase III and the protein then called Csn1. The finding clarified a crucial component of bacterial defence against invading DNA.[10]
Collaboration with Doudna led to Jinek and colleagues’ 2012 paper. It showed that RNA could programme Cas9 to cut a specified DNA sequence.[11]
In 2013, Chylinski, Le Rhun and Charpentier compared tracrRNA and Cas9 families across bacteria. They identified sequence diversity and subgroups of type II CRISPR systems. This comparison expanded understanding of a natural family of mechanisms, supporting the development and selection of editing tools.[12]
Her research continued beyond Cas9. A 2015 study with Le Rhun, Beer, Reimegård and Chylinski used sequencing to identify antisense and small RNAs in S. pyogenes. It also examined RNases’ regulatory roles, expanding the map of mechanisms controlling bacterial gene expression.[13]
Scientific leadership in Berlin
In 2015 she joined the Max Planck Society and led research at its Institute for Infection Biology.[8] In 2018 she founded the Max Planck Unit for the Science of Pathogens on Berlin’s Charité Mitte campus. The centre combines basic research, experimental platforms and scientific training.[14]
Charpentier directs the unit and its international team.[3] In an interview she discussed pathogen regulation, including S. pyogenes, and antimicrobial resistance. Understanding interactions between microorganisms and their environment offers a research route towards identifying medical and biotechnological possibilities.[15]
Companies, licensing and medical applications
In 2013 she cofounded CRISPR Therapeutics with Rodger Novak and Shaun Foy to translate genome editing into therapeutic applications. The initiative brought scientific knowledge together with drug development while Charpentier continued basic research at European academic institutions.[16]
In 2014 she joined Novak and Foy in founding ERS Genomics to facilitate CRISPR-Cas9 intellectual-property licensing. Licensing technology is distinct from developing each product that uses it, with its own participants and responsibilities.[17]
In November 2023 the UK regulator authorised Casgevy, developed by Vertex and CRISPR Therapeutics: the first authorised CRISPR-based medicine. Through clinical and pharmaceutical teams, a platform originating in bacterial research reached treatment of blood disorders.[18]
The US FDA approved Casgevy on 8 December 2023. It uses a patient’s own cells, edited outside the body and subsequently returned. This historical approval illustrates the development required between an initial molecular mechanism and a product evaluated through trials and regulatory review.[19]
Intellectual property
Charpentier, the University of California and the University of Vienna participated in patent litigation. In May 2025 a US court remanded an invention-conception issue for reconsideration.[20]
Nobel Prize, awards and recognition
In 2018 she received the Kavli Prize in Nanoscience with Doudna and Virginijus Šikšnys. It recognised the two researchers’ collaboration and the independent contribution of Šikšnys’s team. Its citation highlighted a molecular-scale tool transforming genetic research and its applications.[21]
She was elected to EMBO in 2014 and Leopoldina in 2015, and became a foreign associate of the US National Academy of Sciences in 2017. Honorary doctorates included Umeå in 2017 and Cambridge in 2018. These honours preceded the Nobel and reflected international recognition.[22]
The French Academy of Sciences elected her in December 2017.[23] In 2023 Umeå named her an honorary citizen for her contribution to the city and its university’s profile, maintaining her connection with the Swedish setting of a decisive stage of her research.[24]
